TALTZ
Taltz (ixekizumab) is an interleukin-17A antagonist indicated for the treatment of several chronic inflammatory conditions in both pediatric and adult populations. It is approved for patients aged six years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The medication is also used to treat adults with active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.
How TALTZ Works
Ixekizumab is a humanized monoclonal antibody that selectively binds to the interleukin 17A (IL-17A) cytokine. By binding to this cytokine, the drug prevents it from interacting with the IL-17 receptor found on various cells. This action inhibits the release of proinflammatory cytokines and chemokines that are typically involved in normal inflammatory and immune responses. Through this targeted blockade, the medication reduces the inflammation associated with specific autoimmune and musculoskeletal disorders.
Details
- Status
- Prescription
- First Approved
- 2016-03-22
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
TALTZ Approval History
What TALTZ Treats
4 indicationsTALTZ is approved for 4 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Moderate-to-severe plaque psoriasis in patients 6 years of age and older
- Active psoriatic arthritis in adults
- Active ankylosing spondylitis in adults
- Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
TALTZ Target & Pathway
ProTarget
A pro-inflammatory cytokine produced by Th17 cells that plays a key role in psoriasis, psoriatic arthritis, and ankylosing spondylitis. Blocking IL-17 reduces the inflammatory cascade that causes skin plaques and joint inflammation.
Drugs Similar to TALTZ
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TALTZ FDA Label Details
ProIndications & Usage
FDA Label (PDF)TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. adults with active psoriatic arthritis. adults with active ankylosing spondylitis. adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. 1.1 Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.